Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 04:30PM GMT
Release Date Price: $94.43 (-0.91%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Hello, and good afternoon. Welcome, again, to the 19th Annual Morgan Stanley Healthcare Conference. Before I get going, let me just go through the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, let me introduce myself. I'm Dave Lebowitz, one of the biotechnology analysts here. I have with me in the next session from Blueprint Medicines COO, Kate Haviland; and President of Research and Development, Fouad Namouni.

Questions & Answers

David Neil Lebowitz
Morgan Stanley, Research Division - VP

I guess if you could start maybe to give a top line description of the company, what has happened? There's certainly been an evolution in the last couple of years, a lot of changes and where you're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot